Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313595 | 0.95 | PDE5A (0.56) | PDE5ACA12CA9TSHRADORA2B | |
| SCHEMBL6312474 | 0.95 | PDE5A (0.58) | PDE5ACA12CA9ALDH1A1MAPK1 | |
| SCHEMBL6312292 | 0.92 | PDE5A (0.54) | PDE5AMAPK1ADORA2BADORA3ADORA1 | |
| SCHEMBL6312534 | 0.90 | PDE5A (0.53) | PDE5ATSHRADORA2BADORA3ADORA1 | |
| SCHEMBL6304667 | 0.86 | PDE5A (0.61) | PDE5ACA12CA9ADORA2BADORA3 | |
| SCHEMBL6307577 | 0.84 | PDE5A (0.55) | PDE5ACA12CA9ALDH1A1MAPK1 | |
| SCHEMBL6305338 | 0.84 | PDE5A (0.57) | PDE5ACA12CA9ALDH1A1MAPK1 | |
| SCHEMBL5829879 | 0.82 | PDE5A (0.53) | PDE5ACA12CA9ALDH1A1MAPK1 | |
| SCHEMBL6314197 | 0.80 | PDE5A (0.54) | PDE5AADORA2BADORA3ADORA1PDE3B | |
| SCHEMBL6312592 | 0.80 | PDE5A (0.58) | PDE5ACA12CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943253-B2 | 6-phenylpyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-09-13 | — | — | US | disclosed |
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PARALLEL WIRELESS, INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232838-A1 | Nitrogen compounds such as 3-Methyl-6-(5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl)-1-propyl-1,5-dihydropyrrolo(3,2-d)pyrimidine-2,4-dione, used for prophylaxis of cardiovascular disorders | PDE5A, PDE2A, PDE3A | PDE5A 1/4885CA12 4166/4885CA9 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.